Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRMA Dermata Therapeutics Inc

Closed 11-15 16:00:00 EST

1.12

-0.07

-5.79%

盘后1.12

+0.00-0.01%

18:29 EST

High1.21	Low1.11	Vol74.60K
Open1.19	D1 Closing1.19	Amplitude8.00%
Mkt Cap2.29M	Tradable Cap1.67M	Total Shares2.04M
T/O85.49K	T/O Rate5.00%	Tradable Shares1.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"DRMA","market":"US","secType":"STK","nameCN":"Dermata Therapeutics Inc","latestPrice":1.1201,"timestamp":1731704400000,"preClose":1.189,"halted":0,"volume":74602,"hourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.1201,"latestTime":"18:29 EST","volume":1718,"amount":1919.3999,"timestamp":1731713393253},"delay":0,"floatShares":1493459,"shares":2040768,"eps":-23.744226,"marketStatus":"Closed","change":-0.0689,"latestTime":"11-15 16:00:00 EST","open":1.19,"high":1.2051,"low":1.11,"amount":85485.5589566,"amplitude":0.079983,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-23.744226,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731920400000},"marketStatusCode":5,"adr":0,"listingDate":1628827200000,"exchange":"NASDAQ","adjPreClose":1.189,"preHourTrading":{"tag":"盘前","latestPrice":1.2099,"preClose":1.16,"latestTime":"09:01 EST","volume":191,"amount":231.0950065,"timestamp":1731679301116},"postHourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.1201,"latestTime":"18:29 EST","volume":1718,"amount":1919.3999,"timestamp":1731713393253},"volumeRatio":0.826538},"requestUrl":"/m/hq/s/DRMA/tweets","defaultTab":"tweets","newsList":[{"id":"2483376412","title":"Life Sciences Investor Forum: Presentations Now Available for Online Viewing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483376412","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483376412?lang=en_us&edition=fundamental","pubTime":"2024-11-15 21:35","pubTimestamp":1731677700,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 15, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held November 14th are now available for online viewing.The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section.Select companies are accepting 1x1 management meeting requests through November 19th.Virtual Investor Conferences  is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-sciences-investor-forum-presentations-133500021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CGTX","BK4179","DRMAW","MBCOF","ZVSA","FET","DRMA","NRBO"],"gpt_icon":0},{"id":"2482170219","title":"Life Sciences Investor Forum Agenda Announced for November 14th","url":"https://stock-news.laohu8.com/highlight/detail?id=2482170219","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482170219?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:35","pubTimestamp":1731418500,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 12, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum to be held November 14th. This event is co-sponsored by Zacks SCR.Individual investors, institutional investors, advisors, and analysts are invited to attend.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.“We’re pleased to feature a group of innovative companies at the upcomingLife Sciences Investor Forum,” said Jason Paltrowitz, Executive Vice President at OTC Markets Group. “Co-sponsored by Zacks Small Cap Research, this virtual conference will provide these companies with the opportunity to share their business strategies and engage more investors.”Virtual Investor Conferences Contact:John M. ViglottiSVP Corporate Services, Investor AccessOTC","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-sciences-investor-forum-agenda-133500963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4590","CGTX","ET","NRBO","DRMA","BK4144","BK4581","FET","BK4561","ZVSA","BK4179","DRMAW","BK4585","BK4588"],"gpt_icon":0},{"id":"2482784952","title":"Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2482784952","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482784952?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:35","pubTimestamp":1731332100,"startTime":"0","endTime":"0","summary":"This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.Outstanding efficacy, safety and tolerability results in a Phase 2b clinical trial in moderate to severe acne. Approaching completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research  clinical trial with topline results expected in Q1 2025. Large, addressable market with approximately 30 million patients in the US alone seeking treatments for acne. Continues discussions with potential botulinum toxin partners to further develop DMT410 for topical delivery of botulinum toxin. Raised $7.8M in gross proceeds from financings completed during 2024. Virtual Investor Conferences ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-therapeutics-present-life-sciences-133500595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4179","FET","DRMA","BK4139","DRMAW","LENZ"],"gpt_icon":0},{"id":"2474837382","title":"Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2474837382","media":"ACCESSWIRE","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474837382?lang=en_us&edition=fundamental","pubTime":"2024-10-09 04:15","pubTimestamp":1728418500,"startTime":"0","endTime":"0","summary":"SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc.  , a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the Company's CEO, Gerry Proehl, will present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15, 2024, at 3:30PM ET.Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management. They also plan to host several topical industry panels that promise to be timely and engaging. To attend, sign up to become an M-Vest member.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-therapeutics-participate-2024-maxim-201500399.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","LENZ","BK4137","NQmain","MNQmain","QLD","SQQQ","BK4007","TQQQ","DRMAW","SMMF","QID",".IXIC","PSQ","BK4211","DRMA","VIRI","BK4139","BK4539"],"gpt_icon":1},{"id":"2468463335","title":"Dermata Therapeutics files to sell 5.87M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2468463335","media":"seekingalpha","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468463335?lang=en_us&edition=fundamental","pubTime":"2024-09-20 04:56","pubTimestamp":1726779394,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics (NASDAQ:DRMA) filed to sell 5.87M shares of common stock for holders.\nThis preliminary prospectus is not an offer to sell.\nFiling","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4151406-dermata-therapeutics-files-to-sell-587m-shares-of-common-stock-for-holders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":[".IXIC","MNQmain","NQmain","TQQQ","BK4139","BK4539","QID","SQQQ","PSQ","DRMA","BK4007","LENZ","QLD"],"gpt_icon":0},{"id":"2468351744","title":"Traders Eye Fed Meeting as US Equity Futures Gain Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2468351744","media":"MT Newswires Live","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468351744?lang=en_us&edition=fundamental","pubTime":"2024-09-17 21:09","pubTimestamp":1726578573,"startTime":"0","endTime":"0","summary":"US equity futures posted gains before Tuesday's opening bell as traders looked ahead to the Federal Reserve's decision on monetary policy.Dow Jones Industrial Average futures gained 0.3%, S&P 500 futu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EQR","BK4588","BK4532","IE00BMPRXQ63.HKD","BK4515","NCPL","UDOW","BK4215","US12M.BOND","IE0034235303.USD","BK4559","LU0096362180.USD","US6M.BOND",".IXIC",".SPX","BK4592","IE00BK4W5M84.HKD","HPE","DRMA","SDOW","MNQmain","US2Y.BOND","US7Y.BOND","BK4220","DOG","TQQQ","US10Y.BOND","US30Y.BOND","LU0061474960.USD","DDM","INTC",".DJI","DJX","NQmain","AMZN","SQQQ","US3Y.BOND","IE00B775H168.HKD","QLD","IE00BKPKM429.USD","IE0004091025.USD","LU0048584097.USD","PSQ","DXD","US5Y.BOND","IE00BJJMRX11.SGD","IE00BMPRXN33.USD","QID","BK4122"],"gpt_icon":1},{"id":"2468353439","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2468353439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468353439?lang=en_us&edition=fundamental","pubTime":"2024-09-17 19:48","pubTimestamp":1726573691,"startTime":"0","endTime":"0","summary":"Netcapital  shares slumped 28% pre-bell Tuesday after the company reported a wider fiscal Q1 loss on lower revenue.Bone Biologics  shares fell 15%, paring Monday's 136% rally.Dermata Therapeutics  shares were down 9% after the company priced a $3.5 million private placement of common shares and warrants.Price: 2.1200, Change: -0.76, Percent Change: -26.39","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4135","BK4139","BK4539","DRMA","BK4007","BBLG","NCPL"],"gpt_icon":0},{"id":"2468496381","title":"Dermata Therapeutics prices $3.5M equity offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2468496381","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468496381?lang=en_us&edition=fundamental","pubTime":"2024-09-17 12:54","pubTimestamp":1726548888,"startTime":"0","endTime":"0","summary":"Late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases - Dermata Therapeutics announcedthe sale of 1.91M shares and warrants to purchase shares at $1.83 per share.Gross proceeds from the offering are expected to be approximately $3.5M.The closing of the offering is expected to occur on or about September 17, 2024.The company expects to use net proceeds for general corporate purposes.The stock pricedipped 3%on Monday during after-hours of trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4150162-dermata-therapeutics-prices-35m-equity-offering","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LENZ","BK4139","DRMA","BK4007","BK4539"],"gpt_icon":0},{"id":"2468036628","title":"Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2468036628","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468036628?lang=en_us&edition=fundamental","pubTime":"2024-09-17 09:00","pubTimestamp":1726534800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / Dermata Therapeutics, Inc.  , a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,912,569 shares of common stock  and accompanying series A warrants to purchase up to 1,912,569 shares of common stock and short-term series B warrants to purchase up to 1,912,569 shares of common stock at a purchase price of $1.83 per share of common stock  and accompanying series warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The series A warrants and series B warrants will have an exercise price of $1.58 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the issuance date and the series B warrants will expire eighteen months from the issuance date. The closing of ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-therapeutics-announces-3-5-010000805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP","BK4112","BK4007","LENZ","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","DRMAW","BK4585","BK4539","DRMA","NDAQ","LU2210150020.SGD",".IXIC","BK4588","BK4139","LU2210149790.SGD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2467843302","title":"Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September","url":"https://stock-news.laohu8.com/highlight/detail?id=2467843302","media":"Benzinga","labels":["Economic Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467843302?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:42","pubTimestamp":1726494128,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/09/40878911/dow-jumps-over-200-points-ny-empire-state-manufacturing-index-increases-in-september","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Economic Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCNA","BK4160","NQmain","DXF","IMMP","DRMA",".IXIC","BK4099","QID","TQQQ","BBLG","MNQmain","BK4007","QLD","AMD","PCOM","NVDA","BK4164","PSQ","MU","BK4139","NWTN","BK4122","ESRT","BK4539","SQQQ","INTC"],"gpt_icon":1},{"id":"2467819297","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2467819297","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467819297?lang=en_us&edition=fundamental","pubTime":"2024-09-16 19:32","pubTimestamp":1726486336,"startTime":"0","endTime":"0","summary":"NuCana  shares were up 200% pre-bell Monday after the company said that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.Dermata Therapeutics  stock was over 64% higher following a 6.8% rise in the previous session.Exicure  shares were up 43%, adding to Friday's 5.3% increase.Agape ATP  stock was 26% higher, extending Friday's rally.Nuvalent  shares were up nearly 16% after Friday's 7.1% rise.Price: 7.6200, Change: +5.08, Percent Change: +200.00","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","BK4539","BK4175","DRMA","NUVL","XCUR","NCNA","ATPC"],"gpt_icon":0},{"id":"2465577189","title":"Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2465577189","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465577189?lang=en_us&edition=fundamental","pubTime":"2024-09-06 04:05","pubTimestamp":1725566700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc.  , a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced it will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024.The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata, will provide an overview of the Company's business and an update on the Company's Phase 3 acne program during the presentation.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.ddRHF0UKcHn1infwaQ9UQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/4a28447ff42546b492c673d272410285"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dermata-therapeutics-announces-participation-h-200500491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4561","DRMA","LENZ","BK4585","BK4581","BK4588","ET","BK4590","BK4144","BK4139","DRMAW"],"gpt_icon":0},{"id":"2458563325","title":"7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2458563325","media":"InvestorPlace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458563325?lang=en_us&edition=fundamental","pubTime":"2024-08-09 18:45","pubTimestamp":1723200300,"startTime":"0","endTime":"0","summary":"Nio : The company delivered more than 20,000 vehicles for three consecutive months, but investors are staying away.FuelCell Energy : While hydrogen power sounds like a great idea, FuelCell’s revenue is shrinking.Mullen Automotive : Three reverse stock splits can’t keep Mullen from falling below $1 per share again.Keep reading to find more F-rated growth stocks to sell.What do you call a growth stock that isn’t growing any more?And in today’s market, you can ill-afford to a bad investment. The market is in some turmoil this summer.You also need to be able to identify those opportunities rather than F-rated growth stocks that have little, if any, hope of bouncing back in the near future.F-rated growth stocks are typically characterized by weak fundamentals, poor financial health, and inconsistent performance, which can lead to substantial losses.Nio gets a “D” rating for growth and an “F” rating overall in the Portfolio Grader.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/market360/2024/08/7-f-rated-growth-stocks-to-avoid-like-the-plague-in-august-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["SQQQ","LU0823414478.USD","BK4539","QLD","BK4505","BK4099","BK4007","BK4526","NQmain","BK4147","BK4509","BK4548","BK4534","LU2249611893.SGD","TWOU","LU0708995583.HKD","LU1548497426.USD","TQQQ","NIO","EVS.SI","QID","FCEL","LU2357305700.SGD","BK4581","MULN","LU0312595415.SGD","LU0052750758.USD","BK4504","MNQmain","BK4519","PLUG","DRMA","BK4585","LU0320764599.SGD","BK4588","BK4532","SEDG","BK4096","BK4574","BK4204","BK4139","PSQ","09866","BK4531","LU1720051108.HKD","BK4555",".IXIC","BK4541"],"gpt_icon":1},{"id":"2457175513","title":"Dermata Therapeutics GAAP EPS of -$4.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2457175513","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457175513?lang=en_us&edition=fundamental","pubTime":"2024-08-08 22:31","pubTimestamp":1723127516,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics press release  (NASDAQ:DRMA): Q2  GAAP EPS of -$4.18.\nAs of June 30, 2024, the Company had $4.9 million in cash and cash equivalents, compared to $7.4 million as of December 31, 2023.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4137302-dermata-therapeutics-gaap-eps-of-4_18","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LENZ","DRMA"],"gpt_icon":0},{"id":"2453885442","title":"Nasdaq Down 2%; Alphabet Posts Upbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2453885442","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453885442?lang=en_us&edition=fundamental","pubTime":"2024-07-24 22:17","pubTimestamp":1721830639,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/07/39933993/nasdaq-down-2-alphabet-posts-upbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZE","NDAQ",".IXIC","DRMA","GOOG","NUWE","BBLG","GOOGL","VWE"],"gpt_icon":1},{"id":"2453200344","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2453200344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453200344?lang=en_us&edition=fundamental","pubTime":"2024-07-24 19:37","pubTimestamp":1721821032,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics  shares more than doubled, reversing Tuesday's slump.Pieris Pharmaceuticals  shares surged 78% after the company agreed to merge with Palvella Therapeutics in an all-stock deal.Regencell Bioscience  shares advanced 40%, extending Tuesday's rally.Perfect Moment  shares were up 7%, adding to gains from the previous session.Price: 3.2700, Change: +1.97, Percent Change: +151.54","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PMNT","RGC","PIRS","BK4539","BK4007","DRMA","BK4139","BK4202"],"gpt_icon":0},{"id":"2453003476","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2453003476","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453003476?lang=en_us&edition=fundamental","pubTime":"2024-07-24 19:37","pubTimestamp":1721821032,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4007","DRMA","PIRS","RGC","BK4202","BK4539","PMNT","BK4139"],"gpt_icon":0},{"id":"2452545991","title":"BRIEF-Dermata Announces Achievement Of 50% Enrollment In Pivotal Dmt310 Phase 3 Star-1 Clinical Trial For Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2452545991","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452545991?lang=en_us&edition=fundamental","pubTime":"2024-07-17 21:21","pubTimestamp":1721222519,"startTime":"0","endTime":"0","summary":"July 17  - Dermata Therapeutics Inc   :   * DERMATA ANNOUNCES ACHIEVEMENT OF 50% ENROLLMENT IN PIVOTAL DMT310 PHASE 3 STAR-1 CLINICAL TRIAL FOR ACNE   * DERMATA THERAPEUTICS INC - STAR-1 TOPLINE RESULTS EXPECTED IN Q1 OF 2025Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2452972151","title":"Dermata Announces Achievement of 50% Enrollment in Pivotal Dmt310 Phase 3 Star-1 Clinical Trial for Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2452972151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452972151?lang=en_us&edition=fundamental","pubTime":"2024-07-17 21:08","pubTimestamp":1721221682,"startTime":"0","endTime":"0","summary":"Dermata Announces Achievement of 50% Enrollment in Pivotal Dmt310 Phase 3 Star-1 Clinical Trial for Acne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240717:nFWN3J90KU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","DRMA","BK4007","BK4139"],"gpt_icon":0},{"id":"2452514501","title":"Dermata Therapeutics Inc - Star-1 Topline Results Expected in Q1 of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2452514501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452514501?lang=en_us&edition=fundamental","pubTime":"2024-07-17 21:08","pubTimestamp":1721221682,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc - Star-1 Topline Results Expected in Q1 of 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240717:nFWN3J90KU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","BK4539","DRMA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dermatarx.com","stockEarnings":[{"period":"1week","weight":-0.1127},{"period":"1month","weight":-0.0783},{"period":"3month","weight":-0.3934},{"period":"6month","weight":-0.7169},{"period":"1year","weight":-0.8784},{"period":"ytd","weight":-0.8701}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.077706},{"month":2,"riseRate":0,"avgChangeRate":-0.189434},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.259552},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.036144},{"month":5,"riseRate":0,"avgChangeRate":-0.161766},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.170765},{"month":7,"riseRate":0,"avgChangeRate":-0.19948},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.017932},{"month":9,"riseRate":0,"avgChangeRate":-0.12901},{"month":10,"riseRate":0.5,"avgChangeRate":-0.090426},{"month":11,"riseRate":0.25,"avgChangeRate":-0.058832},{"month":12,"riseRate":0,"avgChangeRate":-0.302578}],"exchange":"NASDAQ","name":"Dermata Therapeutics Inc","nameEN":"Dermata Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Dermata Therapeutics Inc,DRMA,Dermata Therapeutics Inc股票,Dermata Therapeutics Inc股票老虎,Dermata Therapeutics Inc股票老虎国际,Dermata Therapeutics Inc行情,Dermata Therapeutics Inc股票行情,Dermata Therapeutics Inc股价,Dermata Therapeutics Inc股市,Dermata Therapeutics Inc股票价格,Dermata Therapeutics Inc股票交易,Dermata Therapeutics Inc股票购买,Dermata Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction